EMEA-001693-PIP03-21 - paediatric investigation plan

Reparixin

Key facts

• Active Substance:
  Reparixin
• Therapeutic area:
  Infectious diseases
• Decision number:
  P/0210/2022
• PIP number:
  EMEA-001693-PIP03-21
• Pharmaceutical form(s):
  • Age appropriate oral formulation
  • Tablet
• Condition(s) / indication(s):
  Treatment of Coronavirus disease 2019 (COVID-19)
• Route(s) of administration:
  Oral use
• Contact for public enquiries:

  Dompé farmaceutici S.p.A.

  E-mail: [e-mail]

  Tel. [phone]

• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  10/06/2022

Decision

P/0210/2022 : EMA decision of 10 June 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral for reparixin (EMEA-001693-PIP03-21)

Reference Number: EMA/365815/2022